The USA animal model market valuation reached around US$ 947.3 million back in 2022. The demand in the USA animal model is set to increase at a 4.3% CAGR from 2023 to 2033. The demand for animal models in the United States, in terms of value, is anticipated to reach US$ 1,487.9 million by 2033. According to a study by Future Market Insights, mice held a substantial share of over 61.03% in 2022 within the USA market.
| Data Points | Market Insights |
|---|---|
| USA Animal Model Market Value (2022) | US$ 947.3 million |
| USA Animal Model Market Estimated Value (2023) | US$ 976.1 million |
| USA Animal Model Market Projected Value (2033) | US$ 1,487.9 million |
| USA Animal Model Market Value-based CAGR (2022 to 2032) | 4.3% |
The animal model plays a valuable role in clinical research for the development of new drugs and treatments. Almost 90% of the processes for the development of drugs are depended on the testing of animal models.
Noticeable similarities, such as anatomical and physiological similarities, in humans and animals make animal models essential for biological research and drug development. Furthermore, the growing need for novel drugs and customized medicines might boost the demand for animal
The rising trend of genetically modified animal models, such as genetically engineered mice for the study of genetic diseases, multifactorial and polygenic (complex) disorders, neurodegenerative diseases, and inflammatory diseases, is boosting the growth in the market. In 2021, the USA animal model held nearly 60% of the global animal model market worth US$ 1.5 billion.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Demand in the USA animal model market increased at a 3% CAGR between 2017 and 2022. Sales are projected to expand at a 4.3% CAGR over the forecast period due to the growing demand for animal models for regenerative medicine and tissue engineering.
The presence and dominance of CROs in the country, which involve animal models in their research, and increasing focus on personalized medications are key factors expected to drive demand in the USA.
Due to the advent of COVID-19, people gave priority to being fully vaccinated. The demand for clinical research and studies increased with increasing vaccination rates and rising awareness. This directly impacted the demand for animal models as it is used in the development of various vaccines.
Ongoing research and development in the healthcare sector for the development of regenerative medicine and tissue engineering are propelling demand for an animal model. Growing usage of animal model-based preclinical interpretation of new therapeutics and drug discovery & development might fuel sales in the market.
Animal models are effective tools for conducting preclinical; studies to learn about human biology. Factors driving the development and usage of animal models are:
The increasing prevalence of diseases is compelling the government to focus on preventive measures. This is driving investments for performing clinical trials on animal models. For instance, in March 2020, the FDA spent around US$ 250,000 on testing coronavirus on animal models including monkeys, mice, ferrets, and others.
Hefty investments and policy reforms by the government have stimulated funding schemes with regard to animal model research, which is creating opportunities for growth in the market. In addition to this, different species of animal models have different anatomy, physiology, lifespan, and disease characteristics. Therefore, some experiments on animals do not provide conclusive information on patient outcomes. For accurate clinical research in the discovery of drugs, there is still a need for perfect genetically modified animal models.
Animal model providers are benefitting from the next-generation sequencing technology and genome engineering tools. They provide custom and rare disease models, with a focus on supporting personalized therapy drug trials. For instance,
Principal Consultant
Delays in drug approvals and reduced possibilities of medication for human use can hamper the growth of the animal model market. Drugs that survive clinical trials and get approved are sometimes recalled because of toxicity identified in them after a few months or years.
Some animal models have a limited ability to mimic proper complex processes of human physiology, progression, and carcinogenesis. Due to this, safety and efficacy identified in animal studies sometimes cannot be considered for humans. In many cases, certain mouse models’ physiological changes occur in the spectrum that does not occur in human disease.
Some animal model tests take months or years to conduct and analyze. For example, around 4-5 years are taken for rodent cancer studies, which involves thousands and sometimes millions of dollars.
Government regulatory agencies and scientific organizations are finding alternative methods due to the high costs of animal model clinical trials. It is to replace animal testing and provide improvements in the safety of new medications for human use. This can hamper the growth of the animal model market.
USA Animal Model Market:
| Attributes | USA Animal Model Market |
|---|---|
| CAGR (2023 to 2033) | 4.3% |
| Market Value (2023) | US$ 976.1 million |
| Growth Factor | Increasing need for research efforts at pharmaceutical and biotechnology firms. |
| Future Opportunities | Making the clinical trials for vaccines & fast-track evaluation of prospective drugs. |
| Market Trends | Federal investment for large research projects and financial support are boosting the demand. |
USA Yeast Extract Market:
| Attributes | USA Yeast Extract Market |
|---|---|
| CAGR (2023 to 2033) | 8.3% |
| Market Value (2023) | US$ 1,291.3 million |
| Growth Factor | The growing adoption of plant-based diets as a taste enhancer and food ingredient. |
| Future Opportunities | Increasing demand for natural ingredients as people become health conscious. |
| Market Trends | To meet customer demand, businesses are investing in research & experiments hugely. |
USA Medical Coding Market:
| Attributes | USA Medical Coding Market |
|---|---|
| CAGR (2023 to 2033) | 8.4% |
| Market Value (2023) | US$ 1,000 million |
| Growth Factor | The rise in medical appointments and hospital admissions in the United States. |
| Future Opportunities | Growing medical tourism sector with appropriate provision for the same. |
| Market Trends | Leading players are collaborating with hospitals to ensure administrative processes. |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Demand in the Mice Model Segment to Retain their Dominance and Gain Momentum
In terms of species, the mice model segment held a market share of around 61.03% in 2022, with sales anticipated to expand at 5.1% through 2033.
Mice models are one of the most important tools for performing preclinical research to acquire insights into human biology as they are genetically similar to humans. These models are created by engrafting human cells or tissues into mice, resulting in the expression of human proteins.
Mice are increasingly being employed as models in biomedical research for HIV/AIDS, cancer, regenerative medicine, hepatitis, and infectious disease research. They are being developed and used in response to a growing need to determine the true effects of medications on humans. Besides this, the increasing focus on researching human-specific infections, therapies, and immunological responses might continue pushing sales in this segment in the forthcoming years.
| Category | By Species |
|---|---|
| Top Segment | Mice |
| Market Share in Percentage | 61.03% |
| Category | By End-user Verticals |
|---|---|
| Top Segment | Academic & Research Institutes |
| Market Share in Percentage | 37.21% |
Sales of Animal Models for Oncology Research to Remain High
Based on therapeutics, the oncology segment held nearly 32.6% of the total market share in 2022, and the trend is expected to continue over the forecast period.
Animal models are widely used in oncology to study the biochemical and physiological processes of the occurrence and development of cancer. They help in determining the appropriate treatment approach for specific cancers.
Presently, there is a huge global burden of chronic diseases, including cancer. In vitro as well as in vivo approaches are being developed to fight against the rising prevalence of cancer. One of the most significant advancements is the development of humanized mouse and rodent models. They offer high prescient power for the viability of standard and novel anti-cancer therapeutics.
Factors such as the importance of personalized medicine, monoclonal antibodies, and the potential to treat diseases easily on a personal level are expected to fuel sales in this segment.
Adoption of Animal Models in Novel Drug Discovery to Increase Further
By application, total sales of animal models in the drug discovery/development segment accounted for 65.4% of the total market share in 2022.
Drug discovery/development is invariably a lengthy and costly process. It begins with the identification and validation of a potential molecular/cellular therapeutic target. It further moves through a series of preclinical and clinical trials, culminating in a series of regulatory approvals. The usage of experimental animal models helps researchers better understand the genesis, pathophysiology, and overall character of human diseases.
Animal models for drug discovery and development have played a crucial role in the characterization of disease pathophysiology and associated mechanisms of injury and target identification. They are also used for the evaluation of novel therapeutic agents for toxicity/safety, pharmacodynamics, and pharmacokinetics. They are also used for the efficacy of the development of safe and effective therapies and cures for diseases and/or symptoms connected with them.
Applications of Animal Models in Academic and Research Institutes might Gain Traction
Based on end users, demand in the academic & research institutes segments was about 37.21% of the total market share in 2022. Growth of this segment can be attributed to the increasing establishment of academic & research institutes for developing drugs and vaccines for various chronic diseases.
Researchers utilize animal models to examine and assemble evidence-based findings to address different health-related problems. The availability of highly qualified and skilled scientists at academic & research institutes might also contribute to the growth of this segment.
The USA animal model market is fragmented with the presence of established as well emerging market players. These players are actively investing in acquisitions, collaborations, and product launches as key strategies. For instance:
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2017 to 2022 |
| Market Analysis | US$ million or billion for Value |
| Key Countries Covered | The United States of America |
| Key Market Segments Covered | By Species, By Technology, By Applications, By Use and By End-user Verticals |
| Key Companies Profiled | Charles River Laboratories; The Jackson Laboratory; Taconic Biosciences, Inc.; Genoway; Envigo (Inotiv, Inc.); Marshall BioResources; Janvier Labs; Applied stem cells; Biocytogen; Transposagen Biopharmaceuticals, Inc. (Hera Bio Labs); Cyagen; Ingenious targeting labs; Crown Bioscience Inc. (JSR Corporation).; Harbour Biomed; Sinclair BioResources; Alpha Genesis Inc.; Creative Animodel; DaVinci Biomedical Research Products, Inc |
| Report Coverage | Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The market is estimated to reach US$ 1,487.9 million by 2033.
Genoway, Cyagen, and Biocytogen are the vital market players.
The market is estimated to secure a valuation of US$ 976.1 million in 2023.
The growth potential of the market is 4.3% through 2033.
Rising need for research efforts at pharmaceutical and biotechnology firms.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Product Life Cycle Analysis 3.5. Supply Chain Analysis 3.5.1. Supply Side Participants and their Roles 3.5.1.1. Producers 3.5.1.2. Mid-Level Participants (Traders/ Agents/ Brokers) 3.5.1.3. Wholesalers and Distributors 3.5.2. Value Added and Value Created at Node in the Supply Chain 3.5.3. List of Raw Material Suppliers 3.5.4. List of Existing and Potential Buyer’s 3.6. Investment Feasibility Matrix 3.7. Value Chain Analysis 3.7.1. Profit Margin Analysis 3.7.2. Wholesalers and Distributors 3.7.3. Retailers 3.8. PESTLE and Porter’s Analysis 3.9. Regulatory Landscape 3.9.1. By Key Regions 3.9.2. By Key Countries 3.10. Regional Parent Market Outlook 3.11. Production and Consumption Statistics 3.12. Import and Export Statistics 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) & Volume (Units) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) & Volume (Units) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Species 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Species, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Species, 2023 to 2033 5.3.1. Mouse 5.3.2. Rat 5.3.3. Zebrafish 5.3.4. Rabbit 5.3.5. Guinea pig 5.3.6. Others 5.4. Y-o-Y Growth Trend Analysis By Species, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Species, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapeutics 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Therapeutics, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Therapeutics, 2023 to 2033 6.3.1. Oncology 6.3.2. Cardiovascular diseases 6.3.3. Neurological disorders 6.3.4. Immunological disorders 6.3.5. Genetic disorders 6.3.6. Others 6.4. Y-o-Y Growth Trend Analysis By Therapeutics, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Therapeutics, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Applications 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Applications, 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Applications, 2023 to 2033 7.3.1. Drug discovery and development 7.3.2. Basic research 7.3.3. Toxicology 7.3.4. Preclinical testing 7.3.5. Others 7.4. Y-o-Y Growth Trend Analysis By Applications, 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Applications, 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-users 8.1. Introduction / Key Findings 8.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By End-users, 2018 to 2022 8.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By End-users, 2023 to 2033 8.3.1. Pharmaceutical and biotechnology companies 8.3.2. Academic and research institutes 8.3.3. Contract research organizations (CROs) 8.3.4. Government and regulatory agencies 8.4. Y-o-Y Growth Trend Analysis By End-users, 2018 to 2022 8.5. Absolute $ Opportunity Analysis By End-users, 2023 to 2033 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 9.1. Introduction 9.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Region, 2018 to 2022 9.3. Current Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Region, 2023 to 2033 9.3.1. North America 9.3.2. Latin America 9.3.3. Europe 9.3.4. Asia Pacific 9.3.5. MEA 9.4. Market Attractiveness Analysis By Region 10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. The USA 10.2.1.2. Canada 10.2.2. By Species 10.2.3. By Therapeutics 10.2.4. By Applications 10.2.5. By End-users 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Species 10.3.3. By Therapeutics 10.3.4. By Applications 10.3.5. By End-users 10.4. Key Takeaways 11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Brazil 11.2.1.2. Mexico 11.2.1.3. Rest of Latin America 11.2.2. By Species 11.2.3. By Therapeutics 11.2.4. By Applications 11.2.5. By End-users 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Species 11.3.3. By Therapeutics 11.3.4. By Applications 11.3.5. By End-users 11.4. Key Takeaways 12. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. Germany 12.2.1.2. United Kingdom 12.2.1.3. France 12.2.1.4. Spain 12.2.1.5. Italy 12.2.1.6. Rest of Europe 12.2.2. By Species 12.2.3. By Therapeutics 12.2.4. By Applications 12.2.5. By End-users 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Species 12.3.3. By Therapeutics 12.3.4. By Applications 12.3.5. By End-users 12.4. Key Takeaways 13. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.1.4. Singapore 13.2.1.5. Thailand 13.2.1.6. Indonesia 13.2.1.7. Australia 13.2.1.8. New Zealand 13.2.1.9. Rest of Asia Pacific 13.2.2. By Species 13.2.3. By Therapeutics 13.2.4. By Applications 13.2.5. By End-users 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Species 13.3.3. By Therapeutics 13.3.4. By Applications 13.3.5. By End-users 13.4. Key Takeaways 14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. GCC Countries 14.2.1.2. South Africa 14.2.1.3. Israel 14.2.1.4. Rest of MEA 14.2.2. By Species 14.2.3. By Therapeutics 14.2.4. By Applications 14.2.5. By End-users 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Species 14.3.3. By Therapeutics 14.3.4. By Applications 14.3.5. By End-users 14.4. Key Takeaways 15. Key Countries Market Analysis 15.1. USA 15.1.1. Pricing Analysis 15.1.2. Market Share Analysis, 2022 15.1.2.1. By Species 15.1.2.2. By Therapeutics 15.1.2.3. By Applications 15.1.2.4. By End-users 15.2. Canada 15.2.1. Pricing Analysis 15.2.2. Market Share Analysis, 2022 15.2.2.1. By Species 15.2.2.2. By Therapeutics 15.2.2.3. By Applications 15.2.2.4. By End-users 15.3. Brazil 15.3.1. Pricing Analysis 15.3.2. Market Share Analysis, 2022 15.3.2.1. By Species 15.3.2.2. By Therapeutics 15.3.2.3. By Applications 15.3.2.4. By End-users 15.4. Mexico 15.4.1. Pricing Analysis 15.4.2. Market Share Analysis, 2022 15.4.2.1. By Species 15.4.2.2. By Therapeutics 15.4.2.3. By Applications 15.4.2.4. By End-users 15.5. Germany 15.5.1. Pricing Analysis 15.5.2. Market Share Analysis, 2022 15.5.2.1. By Species 15.5.2.2. By Therapeutics 15.5.2.3. By Applications 15.5.2.4. By End-users 15.6. United Kingdom 15.6.1. Pricing Analysis 15.6.2. Market Share Analysis, 2022 15.6.2.1. By Species 15.6.2.2. By Therapeutics 15.6.2.3. By Applications 15.6.2.4. By End-users 15.7. France 15.7.1. Pricing Analysis 15.7.2. Market Share Analysis, 2022 15.7.2.1. By Species 15.7.2.2. By Therapeutics 15.7.2.3. By Applications 15.7.2.4. By End-users 15.8. Spain 15.8.1. Pricing Analysis 15.8.2. Market Share Analysis, 2022 15.8.2.1. By Species 15.8.2.2. By Therapeutics 15.8.2.3. By Applications 15.8.2.4. By End-users 15.9. Italy 15.9.1. Pricing Analysis 15.9.2. Market Share Analysis, 2022 15.9.2.1. By Species 15.9.2.2. By Therapeutics 15.9.2.3. By Applications 15.9.2.4. By End-users 15.10. China 15.10.1. Pricing Analysis 15.10.2. Market Share Analysis, 2022 15.10.2.1. By Species 15.10.2.2. By Therapeutics 15.10.2.3. By Applications 15.10.2.4. By End-users 15.11. Japan 15.11.1. Pricing Analysis 15.11.2. Market Share Analysis, 2022 15.11.2.1. By Species 15.11.2.2. By Therapeutics 15.11.2.3. By Applications 15.11.2.4. By End-users 15.12. South Korea 15.12.1. Pricing Analysis 15.12.2. Market Share Analysis, 2022 15.12.2.1. By Species 15.12.2.2. By Therapeutics 15.12.2.3. By Applications 15.12.2.4. By End-users 15.13. Singapore 15.13.1. Pricing Analysis 15.13.2. Market Share Analysis, 2022 15.13.2.1. By Species 15.13.2.2. By Therapeutics 15.13.2.3. By Applications 15.13.2.4. By End-users 15.14. Thailand 15.14.1. Pricing Analysis 15.14.2. Market Share Analysis, 2022 15.14.2.1. By Species 15.14.2.2. By Therapeutics 15.14.2.3. By Applications 15.14.2.4. By End-users 15.15. Indonesia 15.15.1. Pricing Analysis 15.15.2. Market Share Analysis, 2022 15.15.2.1. By Species 15.15.2.2. By Therapeutics 15.15.2.3. By Applications 15.15.2.4. By End-users 15.16. Australia 15.16.1. Pricing Analysis 15.16.2. Market Share Analysis, 2022 15.16.2.1. By Species 15.16.2.2. By Therapeutics 15.16.2.3. By Applications 15.16.2.4. By End-users 15.17. New Zealand 15.17.1. Pricing Analysis 15.17.2. Market Share Analysis, 2022 15.17.2.1. By Species 15.17.2.2. By Therapeutics 15.17.2.3. By Applications 15.17.2.4. By End-users 15.18. GCC Countries 15.18.1. Pricing Analysis 15.18.2. Market Share Analysis, 2022 15.18.2.1. By Species 15.18.2.2. By Therapeutics 15.18.2.3. By Applications 15.18.2.4. By End-users 15.19. South Africa 15.19.1. Pricing Analysis 15.19.2. Market Share Analysis, 2022 15.19.2.1. By Species 15.19.2.2. By Therapeutics 15.19.2.3. By Applications 15.19.2.4. By End-users 15.20. Israel 15.20.1. Pricing Analysis 15.20.2. Market Share Analysis, 2022 15.20.2.1. By Species 15.20.2.2. By Therapeutics 15.20.2.3. By Applications 15.20.2.4. By End-users 16. Market Structure Analysis 16.1. Competition Dashboard 16.2. Competition Benchmarking 16.3. Market Share Analysis of Top Players 16.3.1. By Regional 16.3.2. By Species 16.3.3. By Therapeutics 16.3.4. By Applications 16.3.5. By End-users 17. Competition Analysis 17.1. Competition Deep Dive 17.1.1. Charles River Laboratories 17.1.1.1. Overview 17.1.1.2. Product Portfolio 17.1.1.3. Profitability by Market Segments 17.1.1.4. Sales Footprint 17.1.1.5. Strategy Overview 17.1.1.5.1. Marketing Strategy 17.1.1.5.2. Product Strategy 17.1.1.5.3. Channel Strategy 17.1.2. The Jackson Laboratory 17.1.2.1. Overview 17.1.2.2. Product Portfolio 17.1.2.3. Profitability by Market Segments 17.1.2.4. Sales Footprint 17.1.2.5. Strategy Overview 17.1.2.5.1. Marketing Strategy 17.1.2.5.2. Product Strategy 17.1.2.5.3. Channel Strategy 17.1.3. Taconic Biosciences, Inc. 17.1.3.1. Overview 17.1.3.2. Product Portfolio 17.1.3.3. Profitability by Market Segments 17.1.3.4. Sales Footprint 17.1.3.5. Strategy Overview 17.1.3.5.1. Marketing Strategy 17.1.3.5.2. Product Strategy 17.1.3.5.3. Channel Strategy 17.1.4. Genoway 17.1.4.1. Overview 17.1.4.2. Product Portfolio 17.1.4.3. Profitability by Market Segments 17.1.4.4. Sales Footprint 17.1.4.5. Strategy Overview 17.1.4.5.1. Marketing Strategy 17.1.4.5.2. Product Strategy 17.1.4.5.3. Channel Strategy 17.1.5. Envigo (Inotiv, Inc.) 17.1.5.1. Overview 17.1.5.2. Product Portfolio 17.1.5.3. Profitability by Market Segments 17.1.5.4. Sales Footprint 17.1.5.5. Strategy Overview 17.1.5.5.1. Marketing Strategy 17.1.5.5.2. Product Strategy 17.1.5.5.3. Channel Strategy 17.1.6. Marshall BioResources 17.1.6.1. Overview 17.1.6.2. Product Portfolio 17.1.6.3. Profitability by Market Segments 17.1.6.4. Sales Footprint 17.1.6.5. Strategy Overview 17.1.6.5.1. Marketing Strategy 17.1.6.5.2. Product Strategy 17.1.6.5.3. Channel Strategy 17.1.7. Janvier Labs 17.1.7.1. Overview 17.1.7.2. Product Portfolio 17.1.7.3. Profitability by Market Segments 17.1.7.4. Sales Footprint 17.1.7.5. Strategy Overview 17.1.7.5.1. Marketing Strategy 17.1.7.5.2. Product Strategy 17.1.7.5.3. Channel Strategy 17.1.8. Applied stem cells 17.1.8.1. Overview 17.1.8.2. Product Portfolio 17.1.8.3. Profitability by Market Segments 17.1.8.4. Sales Footprint 17.1.8.5. Strategy Overview 17.1.8.5.1. Marketing Strategy 17.1.8.5.2. Product Strategy 17.1.8.5.3. Channel Strategy 17.1.9. Biocytogen 17.1.9.1. Overview 17.1.9.2. Product Portfolio 17.1.9.3. Profitability by Market Segments 17.1.9.4. Sales Footprint 17.1.9.5. Strategy Overview 17.1.9.5.1. Marketing Strategy 17.1.9.5.2. Product Strategy 17.1.9.5.3. Channel Strategy 17.1.10. Transposagen Biopharmaceuticals, Inc. (Hera Bio Labs) 17.1.10.1. Overview 17.1.10.2. Product Portfolio 17.1.10.3. Profitability by Market Segments 17.1.10.4. Sales Footprint 17.1.10.5. Strategy Overview 17.1.10.5.1. Marketing Strategy 17.1.10.5.2. Product Strategy 17.1.10.5.3. Channel Strategy 17.1.11. Cyagen 17.1.11.1. Overview 17.1.11.2. Product Portfolio 17.1.11.3. Profitability by Market Segments 17.1.11.4. Sales Footprint 17.1.11.5. Strategy Overview 17.1.11.5.1. Marketing Strategy 17.1.11.5.2. Product Strategy 17.1.11.5.3. Channel Strategy 17.1.12. Ingenious targeting labs 17.1.12.1. Overview 17.1.12.2. Product Portfolio 17.1.12.3. Profitability by Market Segments 17.1.12.4. Sales Footprint 17.1.12.5. Strategy Overview 17.1.12.5.1. Marketing Strategy 17.1.12.5.2. Product Strategy 17.1.12.5.3. Channel Strategy 17.1.13. Crown Bioscience Inc. (JSR Corporation). 17.1.13.1. Overview 17.1.13.2. Product Portfolio 17.1.13.3. Profitability by Market Segments 17.1.13.4. Sales Footprint 17.1.13.5. Strategy Overview 17.1.13.5.1. Marketing Strategy 17.1.13.5.2. Product Strategy 17.1.13.5.3. Channel Strategy 17.1.14. Harbour Biomed 17.1.14.1. Overview 17.1.14.2. Product Portfolio 17.1.14.3. Profitability by Market Segments 17.1.14.4. Sales Footprint 17.1.14.5. Strategy Overview 17.1.14.5.1. Marketing Strategy 17.1.14.5.2. Product Strategy 17.1.14.5.3. Channel Strategy 17.1.15. Sinclair BioResources 17.1.15.1. Overview 17.1.15.2. Product Portfolio 17.1.15.3. Profitability by Market Segments 17.1.15.4. Sales Footprint 17.1.15.5. Strategy Overview 17.1.15.5.1. Marketing Strategy 17.1.15.5.2. Product Strategy 17.1.15.5.3. Channel Strategy 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports
USA Animal Model Market
